+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Tumor Targeting Peptides Market - Global Forecast 2026-2032- Product Image
Tumor Targeting Peptides Market - Global Forecast 2026-2032- Product Image
Sale

Tumor Targeting Peptides Market - Global Forecast 2026-2032

  • Report

  • 198 Pages
  • September 2026
  • Region: Global
  • 360iResearch™
  • ID: 6126292
UP TO OFF until Jan 01st 2027
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Tumor Targeting Peptides Market is projected to reach USD 385.09 Million in 2026. It is expected to continue growing at a CAGR of 6.77%, reaching USD 570.50 Million by 2032.

Tumor-Targeting Peptides: Executive Overview

Tumor-targeting peptides are short amino-acid sequences investigated as selective carriers, ligands, imaging agents, and therapeutic components in oncology. Their appeal derives from the ability to recognize molecular features associated with tumors while supporting modular attachment of drugs, radionuclides, diagnostic probes, or nanoparticles. Clinical translation depends on target validation, peptide stability, tissue penetration, pharmacokinetics, manufacturing consistency, and evidence of meaningful patient benefit.

Precision Delivery Is Reshaping Peptide Oncology

The field is shifting from peptide discovery alone toward integrated platform development. Researchers increasingly emphasize high-affinity and high-selectivity binders, protease resistance, improved circulation time, controlled payload release, and compatibility with multimodal treatment. Companion diagnostics, molecular profiling, and patient-selection strategies are becoming important because target expression can vary across tumor types and between patients. Regulatory expectations also favor reproducible characterization, clear mechanisms of action, and clinically relevant safety evidence.

Artificial Intelligence Accelerates Discovery and Design

Artificial intelligence can support tumor-targeting peptide development by ranking candidate sequences, modeling peptide-receptor interactions, predicting stability and toxicity, and optimizing conjugation strategies. Machine-learning workflows may reduce experimental screening requirements when trained on high-quality biological and clinical data. However, algorithmic outputs remain dependent on dataset completeness, assay comparability, and prospective validation. Laboratory testing, pharmacology, toxicology, and clinical studies therefore remain necessary before computationally prioritized candidates can be considered reliable.

Regional Differences Reflect Research and Translation Capacity

North America combines advanced oncology research, biotechnology infrastructure, and established clinical-trial networks. Europe benefits from strong academic collaboration and regulatory coordination, while Asia-Pacific is supported by expanding biomedical capabilities and substantial oncology research activity. Latin America is developing specialized research and clinical capacity, with access, reimbursement, and trial infrastructure remaining important considerations. The Middle East is strengthening precision-medicine initiatives, particularly through centralized healthcare systems, while Africa presents significant unmet oncology needs alongside uneven research infrastructure and access to advanced diagnostics.

Economic and Policy Groups Shape Collaboration

ASEAN countries are relevant to regional clinical development and manufacturing cooperation, although regulatory systems and research capacity differ across members. BRICS economies contribute varied scientific, manufacturing, and healthcare capabilities, with collaboration shaped by national priorities and access conditions. The European Union offers coordinated scientific and regulatory mechanisms alongside diverse healthcare systems. G7 members generally provide mature research ecosystems and stringent evidence requirements. GCC states are investing in healthcare modernization and precision medicine, while NATO countries collectively include many influential biomedical research, procurement, and health-security stakeholders.

Country-Level Capabilities Vary Across Discovery and Access

The United States and Canada provide strong translational research and clinical-development environments. Germany, France, Italy, Spain, and the United Kingdom contribute established academic, pharmaceutical, regulatory, and hospital networks within a broader European ecosystem. China, Japan, South Korea, India, and Australia offer substantial research capacity, with differences in regulatory pathways, manufacturing scale, and clinical-trial execution. Brazil and Mexico are important Latin American settings for oncology research and care delivery, while Russia maintains scientific capabilities shaped by domestic policy and international collaboration conditions.

Prioritize Validation, Patient Selection, and Manufacturing Readiness

Industry leaders should validate targets across representative tumor samples, normal tissues, and clinically relevant disease stages before expanding development programs. Candidate selection should combine binding performance with stability, biodistribution, payload release, immunogenicity, and manufacturability. Development teams should establish biomarker and imaging strategies early, design trials around biologically defined populations, and use standardized assays that support comparison across studies. Partnerships with diagnostic, clinical, and manufacturing specialists can improve translation, while transparent data governance is essential when artificial intelligence is used for design or prioritization.

Methodology Based on Structured Scientific and Clinical Assessment

This executive summary uses a structured qualitative assessment of tumor-targeting peptide development, focusing on biological rationale, delivery applications, translational barriers, artificial-intelligence use, regional research conditions, and healthcare-system factors. Insights are framed from established principles in peptide chemistry, oncology drug development, molecular targeting, diagnostics, and clinical research. Regional, group, and country observations are presented comparatively and do not represent market estimates, market shares, forecasts, or company-specific evaluations.

Translation Will Depend on Selectivity and Clinical Proof

Tumor-targeting peptides offer a flexible foundation for precision oncology, but scientific promise alone does not ensure clinical adoption. Progress will depend on demonstrating selective tumor localization, durable and controllable pharmacology, acceptable safety, scalable production, and measurable patient benefit. Programs that connect computational design with rigorous experimental validation, biomarker-led trials, and practical manufacturing strategies are best positioned to advance from discovery into clinically credible applications.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. New Revenue Opportunities
3.4. Next-Generation Business Models
3.5. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. Tumor Targeting Peptides Market, by Peptide Type
7.1. Introduction
7.2. Cyclic Peptides
7.3. Linear Peptides
7.4. Peptidomimetics
7.5. Self Assembling Peptides
8. Tumor Targeting Peptides Market, by Mechanism
8.1. Introduction
8.2. Active Targeting
8.3. Passive Targeting
9. Tumor Targeting Peptides Market, by Development Stage
9.1. Introduction
9.2. Approved
9.3. Phase I
9.4. Phase II
9.5. Phase III
9.6. Preclinical
10. Tumor Targeting Peptides Market, by Delivery Route
10.1. Introduction
10.2. Intratumoral
10.3. Intravenous
10.4. Oral
10.5. Subcutaneous
11. Tumor Targeting Peptides Market, by Application
11.1. Introduction
11.2. Diagnostics
11.2.1. Biomarker Screening
11.2.2. Liquid Biopsy
11.3. Imaging
11.3.1. Magnetic Resonance Imaging
11.3.2. Optical Imaging
11.3.3. Positron Emission Tomography
11.4. Therapeutics
11.4.1. Immunotherapy
11.4.2. Radiotherapeutics
11.4.3. Targeted Drug Delivery
12. Tumor Targeting Peptides Market, by End User
12.1. Introduction
12.2. Diagnostic Centers
12.3. Hospitals
12.4. Pharmaceutical Companies
12.5. Research Institutes
13. Tumor Targeting Peptides Market, by Region
13.1. Introduction
13.2. Asia-Pacific
13.3. North America
13.4. Latin America
13.5. Europe
13.6. Middle East
13.7. Africa
14. Tumor Targeting Peptides Market, by Group
14.1. Introduction
14.2. ASEAN
14.3. GCC
14.4. European Union
14.5. BRICS
14.6. G7
14.7. NATO
15. Tumor Targeting Peptides Market, by Country
15.1. Introduction
15.2. United States
15.3. Canada
15.4. Mexico
15.5. Brazil
15.6. United Kingdom
15.7. Germany
15.8. France
15.9. Russia
15.10. Italy
15.11. Spain
15.12. China
15.13. India
15.14. Japan
15.15. Australia
15.16. South Korea
16. Competitive Landscape
16.1. Market Share Analysis, 2025
16.2. Market Concentration Analysis, 2025
16.2.1. Concentration Ratio (CR)
16.2.2. Herfindahl Hirschman Index (HHI)
16.3. Recent Developments & Impact Analysis, 2025
16.4. Product Portfolio Analysis, 2025
16.5. Benchmarking Analysis, 2025
17. Company Profiles
17.1. Amgen Inc.
17.2. AstraZeneca PLC
17.3. Bicycle Therapeutics PLC
17.4. Eli Lilly and Company
17.5. Ipsen S.A.
17.6. Medigene AG
17.7. Merck & Co., Inc.
17.8. Novartis AG
17.9. PeptiDream Inc.
17.10. Pfizer Inc.
17.11. Roche Holding AG
18. Key Experts
LIST OF FIGURES
FIGURE 1. Global Tumor Targeting Peptides Market, Years Considered for the Study
FIGURE 2. Global Tumor Targeting Peptides Market, Research Design
FIGURE 3. Global Tumor Targeting Peptides Market, Research Framework
FIGURE 4. Global Tumor Targeting Peptides Market, Data Triangulation
FIGURE 5. Global Tumor Targeting Peptides Market Size, 2017-2032 (USD Million)
FIGURE 6. Global Tumor Targeting Peptides Market Size, by Peptide Type, 2025 vs 2032 (%)
FIGURE 7. Global Tumor Targeting Peptides Market Size, by Peptide Type, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 8. Global Tumor Targeting Peptides Market Size, by Mechanism, 2025 vs 2032 (%)
FIGURE 9. Global Tumor Targeting Peptides Market Size, by Mechanism, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 10. Global Tumor Targeting Peptides Market Size, by Development Stage, 2025 vs 2032 (%)
FIGURE 11. Global Tumor Targeting Peptides Market Size, by Development Stage, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 12. Global Tumor Targeting Peptides Market Size, by Delivery Route, 2025 vs 2032 (%)
FIGURE 13. Global Tumor Targeting Peptides Market Size, by Delivery Route, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 14. Global Tumor Targeting Peptides Market Size, by Application, 2025 vs 2032 (%)
FIGURE 15. Global Tumor Targeting Peptides Market Size, by Application, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 16. Global Tumor Targeting Peptides Market Size, by End User, 2025 vs 2032 (%)
FIGURE 17. Global Tumor Targeting Peptides Market Size, by End User, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 18. Global Tumor Targeting Peptides Market Size, by Region, 2025 vs 2032 (%)
FIGURE 19. Global Tumor Targeting Peptides Market Size, by Region, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 20. Global Tumor Targeting Peptides Market Size, by Group, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 21. Global Tumor Targeting Peptides Market Size, by Country, 2025 vs 2032 (%)
FIGURE 22. Global Tumor Targeting Peptides Market Size, by Country, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 23. Global Tumor Targeting Peptides Market Share, by Key Player, 2025
LIST OF TABLES
TABLE 1. Global Tumor Targeting Peptides Market Segmentation & Coverage
TABLE 2. Global Tumor Targeting Peptides Market Size, 2017-2032 (USD Million)
TABLE 3. Global Tumor Targeting Peptides Market Size, by Peptide Type, 2017-2032 (USD Million)
TABLE 4. Global Cyclic Peptides Market Size, by Region, 2017-2032 (USD Million)
TABLE 5. Global Cyclic Peptides Market Size, by Group, 2017-2032 (USD Million)
TABLE 6. Global Cyclic Peptides Market Size, by Country, 2017-2032 (USD Million)
TABLE 7. Global Linear Peptides Market Size, by Region, 2017-2032 (USD Million)
TABLE 8. Global Linear Peptides Market Size, by Group, 2017-2032 (USD Million)
TABLE 9. Global Linear Peptides Market Size, by Country, 2017-2032 (USD Million)
TABLE 10. Global Peptidomimetics Market Size, by Region, 2017-2032 (USD Million)
TABLE 11. Global Peptidomimetics Market Size, by Group, 2017-2032 (USD Million)
TABLE 12. Global Peptidomimetics Market Size, by Country, 2017-2032 (USD Million)
TABLE 13. Global Self Assembling Peptides Market Size, by Region, 2017-2032 (USD Million)
TABLE 14. Global Self Assembling Peptides Market Size, by Group, 2017-2032 (USD Million)
TABLE 15. Global Self Assembling Peptides Market Size, by Country, 2017-2032 (USD Million)
TABLE 16. Global Tumor Targeting Peptides Market Size, by Mechanism, 2017-2032 (USD Million)
TABLE 17. Global Active Targeting Market Size, by Region, 2017-2032 (USD Million)
TABLE 18. Global Active Targeting Market Size, by Group, 2017-2032 (USD Million)
TABLE 19. Global Active Targeting Market Size, by Country, 2017-2032 (USD Million)
TABLE 20. Global Passive Targeting Market Size, by Region, 2017-2032 (USD Million)
TABLE 21. Global Passive Targeting Market Size, by Group, 2017-2032 (USD Million)
TABLE 22. Global Passive Targeting Market Size, by Country, 2017-2032 (USD Million)
TABLE 23. Global Tumor Targeting Peptides Market Size, by Development Stage, 2017-2032 (USD Million)
TABLE 24. Global Approved Market Size, by Region, 2017-2032 (USD Million)
TABLE 25. Global Approved Market Size, by Group, 2017-2032 (USD Million)
TABLE 26. Global Approved Market Size, by Country, 2017-2032 (USD Million)
TABLE 27. Global Phase I Market Size, by Region, 2017-2032 (USD Million)
TABLE 28. Global Phase I Market Size, by Group, 2017-2032 (USD Million)
TABLE 29. Global Phase I Market Size, by Country, 2017-2032 (USD Million)
TABLE 30. Global Phase II Market Size, by Region, 2017-2032 (USD Million)
TABLE 31. Global Phase II Market Size, by Group, 2017-2032 (USD Million)
TABLE 32. Global Phase II Market Size, by Country, 2017-2032 (USD Million)
TABLE 33. Global Phase III Market Size, by Region, 2017-2032 (USD Million)
TABLE 34. Global Phase III Market Size, by Group, 2017-2032 (USD Million)
TABLE 35. Global Phase III Market Size, by Country, 2017-2032 (USD Million)
TABLE 36. Global Preclinical Market Size, by Region, 2017-2032 (USD Million)
TABLE 37. Global Preclinical Market Size, by Group, 2017-2032 (USD Million)
TABLE 38. Global Preclinical Market Size, by Country, 2017-2032 (USD Million)
TABLE 39. Global Tumor Targeting Peptides Market Size, by Delivery Route, 2017-2032 (USD Million)
TABLE 40. Global Intratumoral Market Size, by Region, 2017-2032 (USD Million)
TABLE 41. Global Intratumoral Market Size, by Group, 2017-2032 (USD Million)
TABLE 42. Global Intratumoral Market Size, by Country, 2017-2032 (USD Million)
TABLE 43. Global Intravenous Market Size, by Region, 2017-2032 (USD Million)
TABLE 44. Global Intravenous Market Size, by Group, 2017-2032 (USD Million)
TABLE 45. Global Intravenous Market Size, by Country, 2017-2032 (USD Million)
TABLE 46. Global Oral Market Size, by Region, 2017-2032 (USD Million)
TABLE 47. Global Oral Market Size, by Group, 2017-2032 (USD Million)
TABLE 48. Global Oral Market Size, by Country, 2017-2032 (USD Million)
TABLE 49. Global Subcutaneous Market Size, by Region, 2017-2032 (USD Million)
TABLE 50. Global Subcutaneous Market Size, by Group, 2017-2032 (USD Million)
TABLE 51. Global Subcutaneous Market Size, by Country, 2017-2032 (USD Million)
TABLE 52. Global Tumor Targeting Peptides Market Size, by Application, 2017-2032 (USD Million)
TABLE 53. Global Diagnostics Market Size, by Region, 2017-2032 (USD Million)
TABLE 54. Global Diagnostics Market Size, by Group, 2017-2032 (USD Million)
TABLE 55. Global Diagnostics Market Size, by Country, 2017-2032 (USD Million)
TABLE 56. Global Biomarker Screening Market Size, by Region, 2017-2032 (USD Million)
TABLE 57. Global Biomarker Screening Market Size, by Group, 2017-2032 (USD Million)
TABLE 58. Global Biomarker Screening Market Size, by Country, 2017-2032 (USD Million)
TABLE 59. Global Liquid Biopsy Market Size, by Region, 2017-2032 (USD Million)
TABLE 60. Global Liquid Biopsy Market Size, by Group, 2017-2032 (USD Million)
TABLE 61. Global Liquid Biopsy Market Size, by Country, 2017-2032 (USD Million)
TABLE 62. Global Imaging Market Size, by Region, 2017-2032 (USD Million)
TABLE 63. Global Imaging Market Size, by Group, 2017-2032 (USD Million)
TABLE 64. Global Imaging Market Size, by Country, 2017-2032 (USD Million)
TABLE 65. Global Magnetic Resonance Imaging Market Size, by Region, 2017-2032 (USD Million)
TABLE 66. Global Magnetic Resonance Imaging Market Size, by Group, 2017-2032 (USD Million)
TABLE 67. Global Magnetic Resonance Imaging Market Size, by Country, 2017-2032 (USD Million)
TABLE 68. Global Optical Imaging Market Size, by Region, 2017-2032 (USD Million)
TABLE 69. Global Optical Imaging Market Size, by Group, 2017-2032 (USD Million)
TABLE 70. Global Optical Imaging Market Size, by Country, 2017-2032 (USD Million)
TABLE 71. Global Positron Emission Tomography Market Size, by Region, 2017-2032 (USD Million)
TABLE 72. Global Positron Emission Tomography Market Size, by Group, 2017-2032 (USD Million)
TABLE 73. Global Positron Emission Tomography Market Size, by Country, 2017-2032 (USD Million)
TABLE 74. Global Therapeutics Market Size, by Region, 2017-2032 (USD Million)
TABLE 75. Global Therapeutics Market Size, by Group, 2017-2032 (USD Million)
TABLE 76. Global Therapeutics Market Size, by Country, 2017-2032 (USD Million)
TABLE 77. Global Immunotherapy Market Size, by Region, 2017-2032 (USD Million)
TABLE 78. Global Immunotherapy Market Size, by Group, 2017-2032 (USD Million)
TABLE 79. Global Immunotherapy Market Size, by Country, 2017-2032 (USD Million)
TABLE 80. Global Radiotherapeutics Market Size, by Region, 2017-2032 (USD Million)
TABLE 81. Global Radiotherapeutics Market Size, by Group, 2017-2032 (USD Million)
TABLE 82. Global Radiotherapeutics Market Size, by Country, 2017-2032 (USD Million)
TABLE 83. Global Targeted Drug Delivery Market Size, by Region, 2017-2032 (USD Million)
TABLE 84. Global Targeted Drug Delivery Market Size, by Group, 2017-2032 (USD Million)
TABLE 85. Global Targeted Drug Delivery Market Size, by Country, 2017-2032 (USD Million)
TABLE 86. Global Tumor Targeting Peptides Market Size, by End User, 2017-2032 (USD Million)
TABLE 87. Global Diagnostic Centers Market Size, by Region, 2017-2032 (USD Million)
TABLE 88. Global Diagnostic Centers Market Size, by Group, 2017-2032 (USD Million)
TABLE 89. Global Diagnostic Centers Market Size, by Country, 2017-2032 (USD Million)
TABLE 90. Global Hospitals Market Size, by Region, 2017-2032 (USD Million)
TABLE 91. Global Hospitals Market Size, by Group, 2017-2032 (USD Million)
TABLE 92. Global Hospitals Market Size, by Country, 2017-2032 (USD Million)
TABLE 93. Global Pharmaceutical Companies Market Size, by Region, 2017-2032 (USD Million)
TABLE 94. Global Pharmaceutical Companies Market Size, by Group, 2017-2032 (USD Million)
TABLE 95. Global Pharmaceutical Companies Market Size, by Country, 2017-2032 (USD Million)
TABLE 96. Global Research Institutes Market Size, by Region, 2017-2032 (USD Million)
TABLE 97. Global Research Institutes Market Size, by Group, 2017-2032 (USD Million)
TABLE 98. Global Research Institutes Market Size, by Country, 2017-2032 (USD Million)
TABLE 99. Global Tumor Targeting Peptides Market Size, by Region, 2017-2032 (USD Million)
TABLE 100. Asia-Pacific Tumor Targeting Peptides Market Size, by Region, 2017-2032 (USD Million)
TABLE 101. Asia-Pacific Tumor Targeting Peptides Market Size, by Peptide Type, 2017-2032 (USD Million)
TABLE 102. Asia-Pacific Tumor Targeting Peptides Market Size, by Mechanism, 2017-2032 (USD Million)
TABLE 103. Asia-Pacific Tumor Targeting Peptides Market Size, by Development Stage, 2017-2032 (USD Million)
TABLE 104. Asia-Pacific Tumor Targeting Peptides Market Size, by Delivery Route, 2017-2032 (USD Million)
TABLE 105. Asia-Pacific Tumor Targeting Peptides Market Size, by Application, 2017-2032 (USD Million)
TABLE 106. Asia-Pacific Tumor Targeting Peptides Market Size, by Diagnostics, 2017-2032 (USD Million)
TABLE 107. Asia-Pacific Tumor Targeting Peptides Market Size, by Imaging, 2017-2032 (USD Million)
TABLE 108. Asia-Pacific Tumor Targeting Peptides Market Size, by Therapeutics, 2017-2032 (USD Million)
TABLE 109. Asia-Pacific Tumor Targeting Peptides Market Size, by End User, 2017-2032 (USD Million)
TABLE 110. North America Tumor Targeting Peptides Market Size, by Region, 2017-2032 (USD Million)
TABLE 111. North America Tumor Targeting Peptides Market Size, by Peptide Type, 2017-2032 (USD Million)
TABLE 112. North America Tumor Targeting Peptides Market Size, by Mechanism, 2017-2032 (USD Million)
TABLE 113. North America Tumor Targeting Peptides Market Size, by Development Stage, 2017-2032 (USD Million)
TABLE 114. North America Tumor Targeting Peptides Market Size, by Delivery Route, 2017-2032 (USD Million)
TABLE 115. North America Tumor Targeting Peptides Market Size, by Application, 2017-2032 (USD Million)
TABLE 116. North America Tumor Targeting Peptides Market Size, by Diagnostics, 2017-2032 (USD Million)
TABLE 117. North America Tumor Targeting Peptides Market Size, by Imaging, 2017-2032 (USD Million)
TABLE 118. North America Tumor Targeting Peptides Market Size, by Therapeutics, 2017-2032 (USD Million)
TABLE 119. North America Tumor Targeting Peptides Market Size, by End User, 2017-2032 (USD Million)
TABLE 120. Latin America Tumor Targeting Peptides Market Size, by Region, 2017-2032 (USD Million)
TABLE 121. Latin America Tumor Targeting Peptides Market Size, by Peptide Type, 2017-2032 (USD Million)
TABLE 122. Latin America Tumor Targeting Peptides Market Size, by Mechanism, 2017-2032 (USD Million)
TABLE 123. Latin America Tumor Targeting Peptides Market Size, by Development Stage, 2017-2032 (USD Million)
TABLE 124. Latin America Tumor Targeting Peptides Market Size, by Delivery Route, 2017-2032 (USD Million)
TABLE 125. Latin America Tumor Targeting Peptides Market Size, by Application, 2017-2032 (USD Million)
TABLE 126. Latin America Tumor Targeting Peptides Market Size, by Diagnostics, 2017-2032 (USD Million)
TABLE 127. Latin America Tumor Targeting Peptides Market Size, by Imaging, 2017-2032 (USD Million)
TABLE 128. Latin America Tumor Targeting Peptides Market Size, by Therapeutics, 2017-2032 (USD Million)
TABLE 129. Latin America Tumor Targeting Peptides Market Size, by End User, 2017-2032 (USD Million)
TABLE 130. Europe Tumor Targeting Peptides Market Size, by Region, 2017-2032 (USD Million)
TABLE 131. Europe Tumor Targeting Peptides Market Size, by Peptide Type, 2017-2032 (USD Million)
TABLE 132. Europe Tumor Targeting Peptides Market Size, by Mechanism, 2017-2032 (USD Million)
TABLE 133. Europe Tumor Targeting Peptides Market Size, by Development Stage, 2017-2032 (USD Million)
TABLE 134. Europe Tumor Targeting Peptides Market Size, by Delivery Route, 2017-2032 (USD Million)
TABLE 135. Europe Tumor Targeting Peptides Market Size, by Application, 2017-2032 (USD Million)
TABLE 136. Europe Tumor Targeting Peptides Market Size, by Diagnostics, 2017-2032 (USD Million)
TABLE 137. Europe Tumor Targeting Peptides Market Size, by Imaging, 2017-2032 (USD Million)
TABLE 138. Europe Tumor Targeting Peptides Market Size, by Therapeutics, 2017-2032 (USD Million)
TABLE 139. Europe Tumor Targeting Peptides Market Size, by End User, 2017-2032 (USD Million)
TABLE 140. Middle East Tumor Targeting Peptides Market Size, by Region, 2017-2032 (USD Million)
TABLE 141. Middle East Tumor Targeting Peptides Market Size, by Peptide Type, 2017-2032 (USD Million)
TABLE 142. Middle East Tumor Targeting Peptides Market Size, by Mechanism, 2017-2032 (USD Million)
TABLE 143. Middle East Tumor Targeting Peptides Market Size, by Development Stage, 2017-2032 (USD Million)
TABLE 144. Middle East Tumor Targeting Peptides Market Size, by Delivery Route, 2017-2032 (USD Million)
TABLE 145. Middle East Tumor Targeting Peptides Market Size, by Application, 2017-2032 (USD Million)
TABLE 146. Middle East Tumor Targeting Peptides Market Size, by Diagnostics, 2017-2032 (USD Million)
TABLE 147. Middle East Tumor Targeting Peptides Market Size, by Imaging, 2017-2032 (USD Million)
TABLE 148. Middle East Tumor Targeting Peptides Market Size, by Therapeutics, 2017-2032 (USD Million)
TABLE 149. Middle East Tumor Targeting Peptides Market Size, by End User, 2017-2032 (USD Million)
TABLE 150. Africa Tumor Targeting Peptides Market Size, by Region, 2017-2032 (USD Million)
TABLE 151. Africa Tumor Targeting Peptides Market Size, by Peptide Type, 2017-2032 (USD Million)
TABLE 152. Africa Tumor Targeting Peptides Market Size, by Mechanism, 2017-2032 (USD Million)
TABLE 153. Africa Tumor Targeting Peptides Market Size, by Development Stage, 2017-2032 (USD Million)
TABLE 154. Africa Tumor Targeting Peptides Market Size, by Delivery Route, 2017-2032 (USD Million)
TABLE 155. Africa Tumor Targeting Peptides Market Size, by Application, 2017-2032 (USD Million)
TABLE 156. Africa Tumor Targeting Peptides Market Size, by Diagnostics, 2017-2032 (USD Million)
TABLE 157. Africa Tumor Targeting Peptides Market Size, by Imaging, 2017-2032 (USD Million)
TABLE 158. Africa Tumor Targeting Peptides Market Size, by Therapeutics, 2017-2032 (USD Million)
TABLE 159. Africa Tumor Targeting Peptides Market Size, by End User, 2017-2032 (USD Million)
TABLE 160. Global Tumor Targeting Peptides Market Size, by Group, 2017-2032 (USD Million)
TABLE 161. ASEAN Tumor Targeting Peptides Market Size, by Group, 2017-2032 (USD Million)
TABLE 162. ASEAN Tumor Targeting Peptides Market Size, by Peptide Type, 2017-2032 (USD Million)
TABLE 163. ASEAN Tumor Targeting Peptides Market Size, by Mechanism, 2017-2032 (USD Million)
TABLE 164. ASEAN Tumor Targeting Peptides Market Size, by Development Stage, 2017-2032 (USD Million)
TABLE 165. ASEAN Tumor Targeting Peptides Market Size, by Delivery Route, 2017-2032 (USD Million)
TABLE 166. ASEAN Tumor Targeting Peptides Market Size, by Application, 2017-2032 (USD Million)
TABLE 167. ASEAN Tumor Targeting Peptides Market Size, by Diagnostics, 2017-2032 (USD Million)
TABLE 168. ASEAN Tumor Targeting Peptides Market Size, by Imaging, 2017-2032 (USD Million)
TABLE 169. ASEAN Tumor Targeting Peptides Market Size, by Therapeutics, 2017-2032 (USD Million)
TABLE 170. ASEAN Tumor Targeting Peptides Market Size, by End User, 2017-2032 (USD Million)
TABLE 171. GCC Tumor Targeting Peptides Market Size, by Group, 2017-2032 (USD Million)
TABLE 172. GCC Tumor Targeting Peptides Market Size, by Peptide Type, 2017-2032 (USD Million)
TABLE 173. GCC Tumor Targeting Peptides Market Size, by Mechanism, 2017-2032 (USD Million)
TABLE 174. GCC Tumor Targeting Peptides Market Size, by Development Stage, 2017-2032 (USD Million)
TABLE 175. GCC Tumor Targeting Peptides Market Size, by Delivery Route, 2017-2032 (USD Million)
TABLE 176. GCC Tumor Targeting Peptides Market Size, by Application, 2017-2032 (USD Million)
TABLE 177. GCC Tumor Targeting Peptides Market Size, by Diagnostics, 2017-2032 (USD Million)
TABLE 178. GCC Tumor Targeting Peptides Market Size, by Imaging, 2017-2032 (USD Million)
TABLE 179. GCC Tumor Targeting Peptides Market Size, by Therapeutics, 2017-2032 (USD Million)
TABLE 180. GCC Tumor Targeting Peptides Market Size, by End User, 2017-2032 (USD Million)
TABLE 181. European Union Tumor Targeting Peptides Market Size, by Group, 2017-2032 (USD Million)
TABLE 182. European Union Tumor Targeting Peptides Market Size, by Peptide Type, 2017-2032 (USD Million)
TABLE 183. European Union Tumor Targeting Peptides Market Size, by Mechanism, 2017-2032 (USD Million)
TABLE 184. European Union Tumor Targeting Peptides Market Size, by Development Stage, 2017-2032 (USD Million)
TABLE 185. European Union Tumor Targeting Peptides Market Size, by Delivery Route, 2017-2032 (USD Million)
TABLE 186. European Union Tumor Targeting Peptides Market Size, by Application, 2017-2032 (USD Million)
TABLE 187. European Union Tumor Targeting Peptides Market Size, by Diagnostics, 2017-2032 (USD Million)
TABLE 188. European Union Tumor Targeting Peptides Market Size, by Imaging, 2017-2032 (USD Million)
TABLE 189. European Union Tumor Targeting Peptides Market Size, by Therapeutics, 2017-2032 (USD Million)
TABLE 190. European Union Tumor Targeting Peptides Market Size, by End User, 2017-2032 (USD Million)
TABLE 191. BRICS Tumor Targeting Peptides Market Size, by Group, 2017-2032 (USD Million)
TABLE 192. BRICS Tumor Targeting Peptides Market Size, by Peptide Type, 2017-2032 (USD Million)
TABLE 193. BRICS Tumor Targeting Peptides Market Size, by Mechanism, 2017-2032 (USD Million)
TABLE 194. BRICS Tumor Targeting Peptides Market Size, by Development Stage, 2017-2032 (USD Million)
TABLE 195. BRICS Tumor Targeting Peptides Market Size, by Delivery Route, 2017-2032 (USD Million)
TABLE 196. BRICS Tumor Targeting Peptides Market Size, by Application, 2017-2032 (USD Million)
TABLE 197. BRICS Tumor Targeting Peptides Market Size, by Diagnostics, 2017-2032 (USD Million)
TABLE 198. BRICS Tumor Targeting Peptides Market Size, by Imaging, 2017-2032 (USD Million)
TABLE 199. BRICS Tumor Targeting Peptides Market Size, by Therapeutics, 2017-2032 (USD Million)
TABLE 200. BRICS Tumor Targeting Peptides Market Size, by End User, 2017-2032 (USD Million)
TABLE 201. G7 Tumor Targeting Peptides Market Size, by Group, 2017-2032 (USD Million)
TABLE 202. G7 Tumor Targeting Peptides Market Size, by Peptide Type, 2017-2032 (USD Million)
TABLE 203. G7 Tumor Targeting Peptides Market Size, by Mechanism, 2017-2032 (USD Million)
TABLE 204. G7 Tumor Targeting Peptides Market Size, by Development Stage, 2017-2032 (USD Million)
TABLE 205. G7 Tumor Targeting Peptides Market Size, by Delivery Route, 2017-2032 (USD Million)
TABLE 206. G7 Tumor Targeting Peptides Market Size, by Application, 2017-2032 (USD Million)
TABLE 207. G7 Tumor Targeting Peptides Market Size, by Diagnostics, 2017-2032 (USD Million)
TABLE 208. G7 Tumor Targeting Peptides Market Size, by Imaging, 2017-2032 (USD Million)
TABLE 209. G7 Tumor Targeting Peptides Market Size, by Therapeutics, 2017-2032 (USD Million)
TABLE 210. G7 Tumor Targeting Peptides Market Size, by End User, 2017-2032 (USD Million)
TABLE 211. NATO Tumor Targeting Peptides Market Size, by Group, 2017-2032 (USD Million)
TABLE 212. NATO Tumor Targeting Peptides Market Size, by Peptide Type, 2017-2032 (USD Million)
TABLE 213. NATO Tumor Targeting Peptides Market Size, by Mechanism, 2017-2032 (USD Million)
TABLE 214. NATO Tumor Targeting Peptides Market Size, by Development Stage, 2017-2032 (USD Million)
TABLE 215. NATO Tumor Targeting Peptides Market Size, by Delivery Route, 2017-2032 (USD Million)
TABLE 216. NATO Tumor Targeting Peptides Market Size, by Application, 2017-2032 (USD Million)
TABLE 217. NATO Tumor Targeting Peptides Market Size, by Diagnostics, 2017-2032 (USD Million)
TABLE 218. NATO Tumor Targeting Peptides Market Size, by Imaging, 2017-2032 (USD Million)
TABLE 219. NATO Tumor Targeting Peptides Market Size, by Therapeutics, 2017-2032 (USD Million)
TABLE 220. NATO Tumor Targeting Peptides Market Size, by End User, 2017-2032 (USD Million)
TABLE 221. Global Tumor Targeting Peptides Market Size, by Country, 2017-2032 (USD Million)
TABLE 222. United States Tumor Targeting Peptides Market Size, 2017-2032 (USD Million)
TABLE 223. United States Tumor Targeting Peptides Market Size, by Peptide Type, 2017-2032 (USD Million)
TABLE 224. United States Tumor Targeting Peptides Market Size, by Mechanism, 2017-2032 (USD Million)
TABLE 225. United States Tumor Targeting Peptides Market Size, by Development Stage, 2017-2032 (USD Million)
TABLE 226. United States Tumor Targeting Peptides Market Size, by Delivery Route, 2017-2032 (USD Million)
TABLE 227. United States Tumor Targeting Peptides Market Size, by Application, 2017-2032 (USD Million)
TABLE 228. United States Tumor Targeting Peptides Market Size, by Diagnostics, 2017-2032 (USD Million)
TABLE 229. United States Tumor Targeting Peptides Market Size, by Imaging, 2017-2032 (USD Million)
TABLE 230. United States Tumor Targeting Peptides Market Size, by Therapeutics, 2017-2032 (USD Million)
TABLE 231. United States Tumor Targeting Peptides Market Size, by End User, 2017-2032 (USD Million)
TABLE 232. Canada Tumor Targeting Peptides Market Size, 2017-2032 (USD Million)
TABLE 233. Canada Tumor Targeting Peptides Market Size, by Peptide Type, 2017-2032 (USD Million)
TABLE 234. Canada Tumor Targeting Peptides Market Size, by Mechanism, 2017-2032 (USD Million)
TABLE 235. Canada Tumor Targeting Peptides Market Size, by Development Stage, 2017-2032 (USD Million)
TABLE 236. Canada Tumor Targeting Peptides Market Size, by Delivery Route, 2017-2032 (USD Million)
TABLE 237. Canada Tumor Targeting Peptides Market Size, by Application, 2017-2032 (USD Million)
TABLE 238. Canada Tumor Targeting Peptides Market Size, by Diagnostics, 2017-2032 (USD Million)
TABLE 239. Canada Tumor Targeting Peptides Market Size, by Imaging, 2017-2032 (USD Million)
TABLE 240. Canada Tumor Targeting Peptides Market Size, by Therapeutics, 2017-2032 (USD Million)
TABLE 241. Canada Tumor Targeting Peptides Market Size, by End User, 2017-2032 (USD Million)
TABLE 242. Mexico Tumor Targeting Peptides Market Size, 2017-2032 (USD Million)
TABLE 243. Mexico Tumor Targeting Peptides Market Size, by Peptide Type, 2017-2032 (USD Million)
TABLE 244. Mexico Tumor Targeting Peptides Market Size, by Mechanism, 2017-2032 (USD Million)
TABLE 245. Mexico Tumor Targeting Peptides Market Size, by Development Stage, 2017-2032 (USD Million)
TABLE 246. Mexico Tumor Targeting Peptides Market Size, by Delivery Route, 2017-2032 (USD Million)
TABLE 247. Mexico Tumor Targeting Peptides Market Size, by Application, 2017-2032 (USD Million)
TABLE 248. Mexico Tumor Targeting Peptides Market Size, by Diagnostics, 2017-2032 (USD Million)
TABLE 249. Mexico Tumor Targeting Peptides Market Size, by Imaging, 2017-2032 (USD Million)
TABLE 250. Mexico Tumor Targeting Peptides Market Size, by Therapeutics, 2017-2032 (USD Million)
TABLE 251. Mexico Tumor Targeting Peptides Market Size, by End User, 2017-2032 (USD Million)
TABLE 252. Brazil Tumor Targeting Peptides Market Size, 2017-2032 (USD Million)
TABLE 253. Brazil Tumor Targeting Peptides Market Size, by Peptide Type, 2017-2032 (USD Million)
TABLE 254. Brazil Tumor Targeting Peptides Market Size, by Mechanism, 2017-2032 (USD Million)
TABLE 255. Brazil Tumor Targeting Peptides Market Size, by Development Stage, 2017-2032 (USD Million)
TABLE 256. Brazil Tumor Targeting Peptides Market Size, by Delivery Route, 2017-2032 (USD Million)
TABLE 257. Brazil Tumor Targeting Peptides Market Size, by Application, 2017-2032 (USD Million)
TABLE 258. Brazil Tumor Targeting Peptides Market Size, by Diagnostics, 2017-2032 (USD Million)
TABLE 259. Brazil Tumor Targeting Peptides Market Size, by Imaging, 2017-2032 (USD Million)
TABLE 260. Brazil Tumor Targeting Peptides Market Size, by Therapeutics, 2017-2032 (USD Million)
TABLE 261. Brazil Tumor Targeting Peptides Market Size, by End User, 2017-2032 (USD Million)
TABLE 262. United Kingdom Tumor Targeting Peptides Market Size, 2017-2032 (USD Million)
TABLE 263. United Kingdom Tumor Targeting Peptides Market Size, by Peptide Type, 2017-2032 (USD Million)
TABLE 264. United Kingdom Tumor Targeting Peptides Market Size, by Mechanism, 2017-2032 (USD Million)
TABLE 265. United Kingdom Tumor Targeting Peptides Market Size, by Development Stage, 2017-2032 (USD Million)
TABLE 266. United Kingdom Tumor Targeting Peptides Market Size, by Delivery Route, 2017-2032 (USD Million)
TABLE 267. United Kingdom Tumor Targeting Peptides Market Size, by Application, 2017-2032 (USD Million)
TABLE 268. United Kingdom Tumor Targeting Peptides Market Size, by Diagnostics, 2017-2032 (USD Million)
TABLE 269. United Kingdom Tumor Targeting Peptides Market Size, by Imaging, 2017-2032 (USD Million)
TABLE 270. United Kingdom Tumor Targeting Peptides Market Size, by Therapeutics, 2017-2032 (USD Million)
TABLE 271. United Kingdom Tumor Targeting Peptides Market Size, by End User, 2017-2032 (USD Million)
TABLE 272. Germany Tumor Targeting Peptides Market Size, 2017-2032 (USD Million)
TABLE 273. Germany Tumor Targeting Peptides Market Size, by Peptide Type, 2017-2032 (USD Million)
TABLE 274. Germany Tumor Targeting Peptides Market Size, by Mechanism, 2017-2032 (USD Million)
TABLE 275. Germany Tumor Targeting Peptides Market Size, by Development Stage, 2017-2032 (USD Million)
TABLE 276. Germany Tumor Targeting Peptides Market Size, by Delivery Route, 2017-2032 (USD Million)
TABLE 277. Germany Tumor Targeting Peptides Market Size, by Application, 2017-2032 (USD Million)
TABLE 278. Germany Tumor Targeting Peptides Market Size, by Diagnostics, 2017-2032 (USD Million)
TABLE 279. Germany Tumor Targeting Peptides Market Size, by Imaging, 2017-2032 (USD Million)
TABLE 280. Germany Tumor Targeting Peptides Market Size, by Therapeutics, 2017-2032 (USD Million)
TABLE 281. Germany Tumor Targeting Peptides Market Size, by End User, 2017-2032 (USD Million)
TABLE 282. France Tumor Targeting Peptides Market Size, 2017-2032 (USD Million)
TABLE 283. France Tumor Targeting Peptides Market Size, by Peptide Type, 2017-2032 (USD Million)
TABLE 284. France Tumor Targeting Peptides Market Size, by Mechanism, 2017-2032 (USD Million)
TABLE 285. France Tumor Targeting Peptides Market Size, by Development Stage, 2017-2032 (USD Million)
TABLE 286. France Tumor Targeting Peptides Market Size, by Delivery Route, 2017-2032 (USD Million)
TABLE 287. France Tumor Targeting Peptides Market Size, by Application, 2017-2032 (USD Million)
TABLE 288. France Tumor Targeting Peptides Market Size, by Diagnostics, 2017-2032 (USD Million)
TABLE 289. France Tumor Targeting Peptides Market Size, by Imaging, 2017-2032 (USD Million)
TABLE 290. France Tumor Targeting Peptides Market Size, by Therapeutics, 2017-2032 (USD Million)
TABLE 291. France Tumor Targeting Peptides Market Size, by End User, 2017-2032 (USD Million)
TABLE 292. Russia Tumor Targeting Peptides Market Size, 2017-2032 (USD Million)
TABLE 293. Russia Tumor Targeting Peptides Market Size, by Peptide Type, 2017-2032 (USD Million)
TABLE 294. Russia Tumor Targeting Peptides Market Size, by Mechanism, 2017-2032 (USD Million)
TABLE 295. Russia Tumor Targeting Peptides Market Size, by Development Stage, 2017-2032 (USD Million)
TABLE 296. Russia Tumor Targeting Peptides Market Size, by Delivery Route, 2017-2032 (USD Million)
TABLE 297. Russia Tumor Targeting Peptides Market Size, by Application, 2017-2032 (USD Million)
TABLE 298. Russia Tumor Targeting Peptides Market Size, by Diagnostics, 2017-2032 (USD Million)
TABLE 299. Russia Tumor Targeting Peptides Market Size, by Imaging, 2017-2032 (USD Million)
TABLE 300. Russia Tumor Targeting Peptides Market Size, by Therapeutics, 2017-2032 (USD Million)
TABLE 301. Russia Tumor Targeting Peptides Market Size, by End User, 2017-2032 (USD Million)
TABLE 302. Italy Tumor Targeting Peptides Market Size, 2017-2032 (USD Million)
TABLE 303. Italy Tumor Targeting Peptides Market Size, by Peptide Type, 2017-2032 (USD Million)
TABLE 304. Italy Tumor Targeting Peptides Market Size, by Mechanism, 2017-2032 (USD Million)
TABLE 305. Italy Tumor Targeting Peptides Market Size, by Development Stage, 2017-2032 (USD Million)
TABLE 306. Italy Tumor Targeting Peptides Market Size, by Delivery Route, 2017-2032 (USD Million)
TABLE 307. Italy Tumor Targeting Peptides Market Size, by Application, 2017-2032 (USD Million)
TABLE 308. Italy Tumor Targeting Peptides Market Size, by Diagnostics, 2017-2032 (USD Million)
TABLE 309. Italy Tumor Targeting Peptides Market Size, by Imaging, 2017-2032 (USD Million)
TABLE 310. Italy Tumor Targeting Peptides Market Size, by Therapeutics, 2017-2032 (USD Million)
TABLE 311. Italy Tumor Targeting Peptides Market Size, by End User, 2017-2032 (USD Million)
TABLE 312. Spain Tumor Targeting Peptides Market Size, 2017-2032 (USD Million)
TABLE 313. Spain Tumor Targeting Peptides Market Size, by Peptide Type, 2017-2032 (USD Million)
TABLE 314. Spain Tumor Targeting Peptides Market Size, by Mechanism, 2017-2032 (USD Million)
TABLE 315. Spain Tumor Targeting Peptides Market Size, by Development Stage, 2017-2032 (USD Million)
TABLE 316. Spain Tumor Targeting Peptides Market Size, by Delivery Route, 2017-2032 (USD Million)
TABLE 317. Spain Tumor Targeting Peptides Market Size, by Application, 2017-2032 (USD Million)
TABLE 318. Spain Tumor Targeting Peptides Market Size, by Diagnostics, 2017-2032 (USD Million)
TABLE 319. Spain Tumor Targeting Peptides Market Size, by Imaging, 2017-2032 (USD Million)
TABLE 320. Spain Tumor Targeting Peptides Market Size, by Therapeutics, 2017-2032 (USD Million)
TABLE 321. Spain Tumor Targeting Peptides Market Size, by End User, 2017-2032 (USD Million)
TABLE 322. China Tumor Targeting Peptides Market Size, 2017-2032 (USD Million)
TABLE 323. China Tumor Targeting Peptides Market Size, by Peptide Type, 2017-2032 (USD Million)
TABLE 324. China Tumor Targeting Peptides Market Size, by Mechanism, 2017-2032 (USD Million)
TABLE 325. China Tumor Targeting Peptides Market Size, by Development Stage, 2017-2032 (USD Million)
TABLE 326. China Tumor Targeting Peptides Market Size, by Delivery Route, 2017-2032 (USD Million)
TABLE 327. China Tumor Targeting Peptides Market Size, by Application, 2017-2032 (USD Million)
TABLE 328. China Tumor Targeting Peptides Market Size, by Diagnostics, 2017-2032 (USD Million)
TABLE 329. China Tumor Targeting Peptides Market Size, by Imaging, 2017-2032 (USD Million)
TABLE 330. China Tumor Targeting Peptides Market Size, by Therapeutics, 2017-2032 (USD Million)
TABLE 331. China Tumor Targeting Peptides Market Size, by End User, 2017-2032 (USD Million)
TABLE 332. India Tumor Targeting Peptides Market Size, 2017-2032 (USD Million)
TABLE 333. India Tumor Targeting Peptides Market Size, by Peptide Type, 2017-2032 (USD Million)
TABLE 334. India Tumor Targeting Peptides Market Size, by Mechanism, 2017-2032 (USD Million)
TABLE 335. India Tumor Targeting Peptides Market Size, by Development Stage, 2017-2032 (USD Million)
TABLE 336. India Tumor Targeting Peptides Market Size, by Delivery Route, 2017-2032 (USD Million)
TABLE 337. India Tumor Targeting Peptides Market Size, by Application, 2017-2032 (USD Million)
TABLE 338. India Tumor Targeting Peptides Market Size, by Diagnostics, 2017-2032 (USD Million)
TABLE 339. India Tumor Targeting Peptides Market Size, by Imaging, 2017-2032 (USD Million)
TABLE 340. India Tumor Targeting Peptides Market Size, by Therapeutics, 2017-2032 (USD Million)
TABLE 341. India Tumor Targeting Peptides Market Size, by End User, 2017-2032 (USD Million)
TABLE 342. Japan Tumor Targeting Peptides Market Size, 2017-2032 (USD Million)
TABLE 343. Japan Tumor Targeting Peptides Market Size, by Peptide Type, 2017-2032 (USD Million)
TABLE 344. Japan Tumor Targeting Peptides Market Size, by Mechanism, 2017-2032 (USD Million)
TABLE 345. Japan Tumor Targeting Peptides Market Size, by Development Stage, 2017-2032 (USD Million)
TABLE 346. Japan Tumor Targeting Peptides Market Size, by Delivery Route, 2017-2032 (USD Million)
TABLE 347. Japan Tumor Targeting Peptides Market Size, by Application, 2017-2032 (USD Million)
TABLE 348. Japan Tumor Targeting Peptides Market Size, by Diagnostics, 2017-2032 (USD Million)
TABLE 349. Japan Tumor Targeting Peptides Market Size, by Imaging, 2017-2032 (USD Million)
TABLE 350. Japan Tumor Targeting Peptides Market Size, by Therapeutics, 2017-2032 (USD Million)
TABLE 351. Japan Tumor Targeting Peptides Market Size, by End User, 2017-2032 (USD Million)
TABLE 352. Australia Tumor Targeting Peptides Market Size, 2017-2032 (USD Million)
TABLE 353. Australia Tumor Targeting Peptides Market Size, by Peptide Type, 2017-2032 (USD Million)
TABLE 354. Australia Tumor Targeting Peptides Market Size, by Mechanism, 2017-2032 (USD Million)
TABLE 355. Australia Tumor Targeting Peptides Market Size, by Development Stage, 2017-2032 (USD Million)
TABLE 356. Australia Tumor Target

Companies Mentioned

  • Amgen Inc.
  • AstraZeneca PLC
  • Bicycle Therapeutics PLC
  • Eli Lilly and Company
  • Ipsen S.A.
  • Medigene AG
  • Merck & Co., Inc.
  • Novartis AG
  • PeptiDream Inc.
  • Pfizer Inc.
  • Roche Holding AG

Related Topics

Related Reports

Peptide-Radionuclide Conjugates Market - Global Forecast 2026-2032 - Product Image

Peptide-Radionuclide Conjugates Market - Global Forecast 2026-2032

  • Report
  • 184 Pages
  • Global
From
Targeted SSTR Radionuclide Drug Conjugates Market - Global Forecast 2026-2032 - Product Image

Targeted SSTR Radionuclide Drug Conjugates Market - Global Forecast 2026-2032

  • Report
  • 185 Pages
  • Global
From
Global Cancer Peptide Drug Market Opportunity, Approved Drug Dosage, Price, Sales & Clinical Trials Insight 2031 - Product Image

Global Cancer Peptide Drug Market Opportunity, Approved Drug Dosage, Price, Sales & Clinical Trials Insight 2031

  • Report
  • 800 Pages
  • Global
From
Peptide Drug Conjugates Market Report 2026 - Product Image

Peptide Drug Conjugates Market Report 2026

  • Report
  • 250 Pages
  • Global
From
Gastroenteropancreatic Neuroendocrine Tumors - Market Insight, Epidemiology, and Market Forecast - 2036 - Product Image

Gastroenteropancreatic Neuroendocrine Tumors - Market Insight, Epidemiology, and Market Forecast - 2036

  • Report
  • 224 Pages
  • Global
From
Copyright © 2002-2026 Research and Markets. All Rights Reserved.